Osteoarthritis (OA) is a degenerative joint disease affecting millions worldwide. Previously viewed as a cartilage issue, it is now recognized as a whole joint disease.
Research has shifted the understanding of OA from mechanical cartilage degradation to immune-mediated breakdown, involving hyperactive matrix metalloproteinases (MMPs) and dysregulated enzymes and cytokines, leading to pain, inflammation, and stiffness.
Advances in diagnostic sciences and molecular biology are revealing new targets and pathways, enhancing OA prognosis and management.
Nerves in the joints, spinal cord and dorsal root ganglia can be damaged during OA. Emerging evidences show that up to 49% of knee OA patients experience neuropathic pain, worsening pain severity and quality of life.
While NSAIDs and other treatments help manage OA, they often fail to address this neuropathic component.
Our Anti-OA formula addresses these issues through multiple mechanisms, managing neuronal and nociceptive pain, mechanical and immune mediated cartilage degradation, peri-articular muscle weakness, and improving knee range of motion.